Phase 2 N=41 Secukinumab for Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,260 A Community-based Assessment of Skin Care, Allergies, and Eczema
Atopic Dermatitis · Atopic Disorders · Eczema
Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019
N/A N=9 Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Atopic Dermatitis · Eczema
Primary: SCORAD Change Score — 33.34 Change Score
N/A N=148,166 Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)
Atopic Dermatitis Eczema · Atopic Dermatitis · Eczema
Primary: Prescription Rates for Atopic Dermatitis Related Treatments: Emollients and Soap Substitutes — 76095 Participants
Phase 2 N=20 Effect of Benralizumab in Atopic Dermatitis
Dermatitis, Atopic · Dermatitis · Eczema
Primary: Number of Allergen-induced Eosinophils in the Skin — 11.95; 71.15 cells/mm2
Phase 3 N=65 8-Week Atopic Dermatitis (AD) Treatment Study
Atopic Dermatitis Eczema
Primary: Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis — -12.2; 9.3; -17.5 units on a scale — p=<0.05
Phase 2 N=60 Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage Change in SCORAD — -18.8; -11.7 percentage change
Phase 2 N=32 Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis
Atopic Dermatitis
Primary: Proportion of SCORAD-50 Response at Week 16. — 5; 3 Participants
Phase 4 N=90 Combination Therapy for Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in the m-EASI (Eczema Area Severity Index) Score. — 5.04; 4.77 units of a 0-12 scale — p=<0.05
Phase 3 N=326 Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects
Atopic Dermatitis
Primary: Percentage of Participants Who Had at Least a 2-grade Reduction From Baseline at Week 6 in the Investigator Global Assessment (IGA) Scale and Had an IGA at Week 6 That…
N/A N=15 Acupressure in Pruritus for Atopic Dermatitis
Atopic Dermatitis
Primary: Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score — 0.8; -5.0 centimeters
Phase 2 N=119 Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
Atopic Dermatitis Eczema
Primary: Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 — -43.5; -62.0 Percent change from baseline
Phase 2 N=185 Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis
Dermatitis, Atopic Dermatitis
Primary: Percentage Change From Baseline in the Eczema Area and Severity Index (EASI) Score at Week 12. — -10.98; -25.99; -31.57 percent change — p=0.1308
Phase 2 N=12 Study of Apremilast in Atopic or Contact Dermatitis
Atopic Dermatitis · Allergic Contact Dermatitis
Primary: Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points — 2 participants
Phase 4 N=100 Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in Three Item Severity Score — -2.6; -3.6 units on a scale
Phase 4 N=39 Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis
Atopic Dermatitis
Primary: Investigator Global Assessment of Improvement — 2; 2; 2 units on a scale
N/A N=368 Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
Dermatitis, Atopic
Primary: Seroprotection, Non-Atopic Dermatitis (AD), Intradermal vs. Moderate to Severe Atopic Dermatitis, Intradermal - Influenza B — 34.4; 22.5 percentage of participants…
Phase 2 N=200 A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier
Dermatitis, Atopic
Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…
Phase 2 N=15 Topical NanoDox® for Atopic Dermatitis
Dermatitis, Atopic
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0 Participants
Phase 2 N=98 A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch) — 7.3; 7.26; 4.27; 4.6 score on a scale — p== 0.249
Phase 3 N=337 Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)
Atopic Dermatitis
Primary: Percentage of Participants Who Had at Least a 2-grade Reduction From Baseline at Week 6 in the Investigator Global Assessment (IGA) Scale and Had an IGA at Week 6 That…
Phase 2 N=40 Topical Roflumilast in Adults With Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD) — -2.30; -1.75 Scores on a scale — p=0.276
Phase 4 N=5 Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Change in Eczema Area Severity Index (EASI) Score From Baseline (Week 1) to Week 16. — 26.4 Scores on a scale.
Phase 3 N=920 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or…
Phase 2 N=102 Oral DS107 in Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Proportion of Patients Achieving an Investigator's Global Assessment (IGA) of 0 (Clear) or 1 (Almost Clear) and a Decrease of at Least 2 Points in IGA at Week 8. — 0.12…
Phase 2 N=50 Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 — -74.45; -41.43 percent change — p=<0.001
Phase 2 N=421 A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Achievement of EASI-50 — 38; 27; 25; 23 Participants
Phase 2 N=250 To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis
Dermatitis, Atopic
Primary: Proportion of Subjects Who Achieve ≥75% Overall Improvement in Eczema Area and Severity Index (EASI) Score From Baseline to Week 16. — 9.8; 18.1; 12.5; 15.1 percentage…
N/A N=82 To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children
Atopic Dermatitis
Primary: Eczema Area and Severity Index (EASI) Score on Day 43 - Change From Baseline — -4.97; -5.01 units on a scale — p=0.9416
Phase 2 N=37 Skin bioMARkers for Atopic Eczema Therapy Evaluation
Atopic Eczema/Dermatitis (Non-Specific)
Primary: Change in Epidermal Thickness — -31.66; -13.76; -28.65; -14.41 µm